Medtronic posts 13.7% revenue growth and raises FY27 guidance

Medtronic reported first-quarter fiscal 2027 revenue of $9.756 billion for the period ended July 31, 2026, up 13.7% from a year earlier, with GAAP diluted EPS of $1.14 and non-GAAP diluted EPS of $1.45. Cardiovascular revenue rose 18.9% organically, while Neuroscience and Medical Surgical increased 9.3% and 10.2%, respectively; Medtronic raised its fiscal 2027 organic revenue growth outlook to 7.25%-7.75% from 6.75%-7.25% and its non-GAAP EPS forecast to $5.94-$6.00.